Sam Brusco, Associate Editor12.15.22
The first patient has been enrolled in Medtronic’s Expand URO U.S. clinical trial for its Hugo robotic-assisted surgery (RAS) system.
The robotic-assisted prostatectomy procedure was performed by Dr. Michael R. Abern at Duke University Hospital.
"This is an exciting moment," Dr. Abern told the press. "Robotic-assisted surgery provides many benefits within my specialty of urology, and I'm proud to have performed the first U.S. clinical trial case with the Medtronic Hugo RAS system."
Urologic procedures are one of the most commonly performed with the help of a surgical robot. Hugo will be used in this study for urologic surgical procedures including radical prostatectomy, radical cystectomy, and nephrectomy (partial or radical) procedures at U.S. sites.
"Scientific evidence is the bedrock of healthcare technology innovation and adoption. It creates and builds trust among clinicians and patients," said Carla Peron, M.D., chief medical officer of Medtronic’s Surgical Robotics business. "We're proud to further that important pursuit with the Hugo RAS system in partnership with hospitals and surgical teams in the United States who share our commitment to patients."
122 patients will be enrolled in the study at six U.S. sites. The Expand URO trial is being conducted thanks to an Investigational Device Exemption (IDE) from the FDA.
Hugo, combined with Medtronic’s Touch Surgery Enterprise provides a smart, digitally enable surgical experience. Outside the U.S., it’s used at hospitals across three continents for procedures in urology, gynecology, and general surgery.
The robotic-assisted prostatectomy procedure was performed by Dr. Michael R. Abern at Duke University Hospital.
"This is an exciting moment," Dr. Abern told the press. "Robotic-assisted surgery provides many benefits within my specialty of urology, and I'm proud to have performed the first U.S. clinical trial case with the Medtronic Hugo RAS system."
Urologic procedures are one of the most commonly performed with the help of a surgical robot. Hugo will be used in this study for urologic surgical procedures including radical prostatectomy, radical cystectomy, and nephrectomy (partial or radical) procedures at U.S. sites.
"Scientific evidence is the bedrock of healthcare technology innovation and adoption. It creates and builds trust among clinicians and patients," said Carla Peron, M.D., chief medical officer of Medtronic’s Surgical Robotics business. "We're proud to further that important pursuit with the Hugo RAS system in partnership with hospitals and surgical teams in the United States who share our commitment to patients."
122 patients will be enrolled in the study at six U.S. sites. The Expand URO trial is being conducted thanks to an Investigational Device Exemption (IDE) from the FDA.
Hugo, combined with Medtronic’s Touch Surgery Enterprise provides a smart, digitally enable surgical experience. Outside the U.S., it’s used at hospitals across three continents for procedures in urology, gynecology, and general surgery.